Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of ICP-332 in prurigo nodularis
CTR20254285Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of soficitinib in prurigo nodularis (PN), sponsored by InnoCare Pharma. Started Nov 2025; status: active.
02
Drugs
soficitinib
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on CTR20254285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254285.